Log in

LON:ONCOncimmune Share Price, Forecast & News

GBX 125
-2.50 (-1.96 %)
(As of 07/10/2020 04:00 PM ET)
Today's Range
Now: GBX 125
50-Day Range
MA: GBX 123.95
52-Week Range
Now: GBX 125
Volume4,828 shs
Average Volume33,554 shs
Market Capitalization£79.38 million
P/E RatioN/A
Dividend YieldN/A
Oncimmune Holdings Plc, an early cancer detection company, develops and commercializes products to diagnose cancer in the United Kingdom and North America. The company engages in the development of autoantibody based platform to allow cancer detection to a range of solid cancer tumor types. It offers EarlyCDT-Lung, a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. The company also develops EarlyCDT-Liver to aid in the detection and confirmation of hepatocellular carcinoma (HCC) in high-risk patients with liver lesions of all sizes tests for liver cancer. Oncimmune Holdings Plc was incorporated in 2015 and is headquartered in Nottingham, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars

Industry, Sector and Symbol

Industry Diagnostics & Research



Sales & Book Value

Annual Sales£358,000.00
Cash FlowGBX 11.40 per share
Book ValueGBX 3.60 per share



Market Cap£79.38 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ONC News and Ratings via Email

Sign-up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.

Oncimmune (LON:ONC) Frequently Asked Questions

How has Oncimmune's stock been impacted by COVID-19 (Coronavirus)?

Oncimmune's stock was trading at GBX 70.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ONC stock has increased by 77.3% and is now trading at GBX 125. View which stocks have been most impacted by Coronavirus.

How were Oncimmune's earnings last quarter?

Oncimmune Holdings PLC (LON:ONC) released its quarterly earnings results on Tuesday, February, 13th. The company reported ($5.70) earnings per share (EPS) for the quarter. The firm earned $0.08 million during the quarter. View Oncimmune's earnings history.

What price target have analysts set for ONC?

0 brokers have issued 12-month target prices for Oncimmune's shares. Their forecasts range from GBX 150 to GBX 150. On average, they anticipate Oncimmune's stock price to reach GBX 150 in the next twelve months. This suggests a possible upside of 20.0% from the stock's current price. View analysts' price targets for Oncimmune.

Has Oncimmune been receiving favorable news coverage?

Press coverage about ONC stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oncimmune earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Oncimmune.

Who are some of Oncimmune's key competitors?

What other stocks do shareholders of Oncimmune own?

Who are Oncimmune's key executives?

Oncimmune's management team includes the following people:
  • Dr. Adam Mark Hill Ph.D., CEO & Director (Age 39)
  • Mr. Andrew Millet BA, FCA, MBA, Exec. (Age 52)
  • Mr. Matthew Hall, Group Chief Financial Officer
  • Dr. Laura J. Peek, Principal Scientist & Assistant Lab Director
  • Mr. Andrew Stewart, Gen. Counsel & Company Sec.

What is Oncimmune's stock symbol?

Oncimmune trades on the London Stock Exchange (LON) under the ticker symbol "ONC."

How do I buy shares of Oncimmune?

Shares of ONC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Oncimmune's stock price today?

One share of ONC stock can currently be purchased for approximately GBX 125.

How big of a company is Oncimmune?

Oncimmune has a market capitalization of £79.38 million and generates £358,000.00 in revenue each year. Oncimmune employs 52 workers across the globe.

What is Oncimmune's official website?

The official website for Oncimmune is oncimmune.com.

How can I contact Oncimmune?

Oncimmune's mailing address is Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The company can be reached via phone at +44-115-8231869.

This page was last updated on 7/12/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.